Reveal Pharmaceuticals

The Gadolinium Free MRI Contrast Agent

Contrast enhanced MRI scans provide crucial medical insight guiding diagnosis, prognosis, and treatment decisions in cancer, multiple sclerosis, stroke, heart disease, vascular conditions, and many other diseases. Contrast enhanced MRIs (CE-MRIs) are essential and irreplaceable, with over 30 million CE-MRI scans performed worldwide each year. We all know someone who has had a contrast enhanced MRI.

Currently, there are no safe MRI contrast agents. Approved agents (GBCAs) contain gadolinium, a heavy metal that causes a continuum of toxicity issues. These range from nephrogenic systemic fibrosis in renally impaired patients, to gadolinium deposition disease in some patients, to brain deposition of gadolinium in all patients. When making the decision to use contrast enhanced MRI physicians and patients have to balance the potential risks from gadolinium with the need for vital medical insight.

Reveal Pharmaceuticals' gadolinium-free MRI contrast agent was designed with the goal of safe CE-MRI for all patients.

Reveal's MRI contrast agent is a direct replacement for all current GBCAs: it will be used for the same disease indications, using existing radiology workflow and protocols.

Reveal's MRI contrast agent was designed to be safe for all patients, including renally impaired patients, for whom all other MRI and CT contrast agents are contraindicated.

Reveal's MRI contrast agent uses manganese, a biocompatible essential element: the human body has natural mechanisms for processing and transporting manganese.